A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

This is a prospective, open-label, multicenter, single-arm clinical study designed to compare the efficacy and safety of neoadjuvant treatment with T-DXd in combination with an immune checkpoint inhibitor in patients with primary intermediate- to high-risk HR-positive, HER2-overexpressing early-stage breast cancer.

NCT Number	NCT06733233
Lead Sponsor	Guangzhou Women and Children's Medical Center
Conditions	Breast Cancer, Estrogen Receptor-Positive, HER2 Low Breast Cancer
Enrollment	23 participants
Start Date	2025-01-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2029-01-01 (estimated)
Updated on ClinicalTrials.gov	2024-12-13